{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:06:28Z","timestamp":1788926788787,"version":"build-2803163510"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Beijing Natural Science Foundation","award":["7232080"],"award-info":[{"award-number":["7232080"]}]},{"name":"the Capital Clinical Diagnostic Techniques and Translational Application Projects","award":["Z221100007422063"],"award-info":[{"award-number":["Z221100007422063"]}]},{"name":"the Capital\u2019s Funds for Health Improvement and Research","award":["2022-1-2172"],"award-info":[{"award-number":["2022-1-2172"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03362-y","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:10:34Z","timestamp":1787202634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of platelets in the hepatocellular carcinoma immune microenvironment and their clinical prospects: a comprehensive review"],"prefix":"10.1007","volume":"43","author":[{"given":"Zirong","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"3362_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"3362_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/cac2.12627","volume":"45","author":"X Diao","year":"2025","unstructured":"Diao X, Guo C, Jin Y, Li B, Gao X, Du X, et al. Cancer situation in China: an analysis based on the global epidemiological data released in 2024. Cancer Commun (Lond Engl). 2025;45:178\u201397. https:\/\/doi.org\/10.1002\/cac2.12627.","journal-title":"Cancer Commun (Lond Engl)"},{"key":"3362_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jhep.2024.10.031","volume":"82","author":"EY Tan","year":"2025","unstructured":"Tan EY, Danpanichkul P, Yong JN, Yu Z, Tan DJH, Lim WH, et al. Liver cancer in 2021: global burden of disease study. J Hepatol. 2025;82:851\u201360. https:\/\/doi.org\/10.1016\/j.jhep.2024.10.031.","journal-title":"J Hepatol"},{"key":"3362_CR4","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","volume":"31","author":"SY Hwang","year":"2025","unstructured":"Hwang SY, Danpanichkul P, Agopian V, Mehta N, Parikh ND, Abou-Alfa GK, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol. 2025;31:S228\u201354. https:\/\/doi.org\/10.3350\/cmh.2024.0824.","journal-title":"Clin Mol Hepatol"},{"key":"3362_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcmgh.2023.09.007","volume":"17","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Luo Y, Liu X, Kiupel M, Li A, Wang H, et al. NCOA5 haploinsufficiency in myeloid-lineage cells sufficiently causes nonalcoholic steatohepatitis and hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 2024;17:1\u201327. https:\/\/doi.org\/10.1016\/j.jcmgh.2023.09.007.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"3362_CR6","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.cgh.2024.01.045","volume":"22","author":"M-H Lee","year":"2024","unstructured":"Lee M-H, Chen Y-T, Huang Y-H, Lu S-N, Yang T-H, Huang J-F, et al. Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC. Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc. 2024;22:1275\u2013e12852. https:\/\/doi.org\/10.1016\/j.cgh.2024.01.045.","journal-title":"Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc"},{"key":"3362_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jhep.2024.08.024","volume":"82","author":"Q Zhong","year":"2025","unstructured":"Zhong Q, Zhou R, Huang Y-N, Huang R-D, Li F-R, Chen H-W, et al. Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases. J Hepatol. 2025;82:427\u201337. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.024.","journal-title":"J Hepatol"},{"key":"3362_CR8","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41575-024-00967-4","volume":"21","author":"L-Y Mak","year":"2024","unstructured":"Mak L-Y, Liu K, Chirapongsathorn S, Yew KC, Tamaki N, Rajaram RB, et al. Liver diseases and hepatocellular carcinoma in the Asia-pacific region: burden, trends, challenges and future directions. Nat Rev Gastroenterol Hepatol. 2024;21:834\u201351. https:\/\/doi.org\/10.1038\/s41575-024-00967-4.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3362_CR9","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1097\/HEP.0000000000000899","volume":"80","author":"F \u00c5berg","year":"2024","unstructured":"\u00c5berg F, Jiang ZG, Cortez-Pinto H, M\u00e4nnist\u00f6 V. Alcohol-associated liver disease-Global epidemiology. Hepatology. 2024;80:1307\u201322. https:\/\/doi.org\/10.1097\/HEP.0000000000000899.","journal-title":"Hepatology"},{"key":"3362_CR10","doi-asserted-by":"publisher","first-page":"e2404089","DOI":"10.1002\/advs.202404089","volume":"12","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Li X, Chen H, Li J, Guo X, Fang Y, et al. Cancer cell-derived exosomal miR-500a-3p modulates hepatic stellate cell activation and the immunosuppressive microenvironment. Adv Sci (Weinh Baden-Wurtt Ger). 2025;12:e2404089. https:\/\/doi.org\/10.1002\/advs.202404089.","journal-title":"Adv Sci (Weinh Baden-Wurtt Ger)"},{"key":"3362_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jcmgh.2024.03.001","volume":"18","author":"J Wang","year":"2024","unstructured":"Wang J, Wang X, Peng H, Dong Z, Liangpunsakul S, Zuo L, et al. Platelets in alcohol-associated liver disease: interaction with neutrophils. Cell Mol Gastroenterol Hepatol. 2024;18:41\u201352. https:\/\/doi.org\/10.1016\/j.jcmgh.2024.03.001.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"3362_CR12","doi-asserted-by":"publisher","first-page":"2455539","DOI":"10.1080\/07853890.2025.2455539","volume":"57","author":"J Wang","year":"2025","unstructured":"Wang J, Qiu K, Zhou S, Gan Y, Jiang K, Wang D, et al. Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis. Ann Med. 2025;57:2455539. https:\/\/doi.org\/10.1080\/07853890.2025.2455539.","journal-title":"Ann Med"},{"key":"3362_CR13","doi-asserted-by":"publisher","first-page":"217044","DOI":"10.1016\/j.canlet.2024.217044","volume":"607","author":"S Bravaccini","year":"2024","unstructured":"Bravaccini S, Boldrin E, Gurioli G, Tedaldi G, Piano MA, Canale M, et al. The use of platelets as a clinical tool in oncology: opportunities and challenges. Cancer Lett. 2024;607:217044. https:\/\/doi.org\/10.1016\/j.canlet.2024.217044.","journal-title":"Cancer Lett"},{"key":"3362_CR14","doi-asserted-by":"publisher","first-page":"113877","DOI":"10.1016\/j.celrep.2024.113877","volume":"43","author":"Z-C Li","year":"2024","unstructured":"Li Z-C, Wang J, Liu H-B, Zheng Y-M, Huang J-H, Cai J-B, et al. Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy. Cell Rep. 2024;43:113877. https:\/\/doi.org\/10.1016\/j.celrep.2024.113877.","journal-title":"Cell Rep"},{"key":"3362_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3390\/cancers11071022","volume":"11","author":"N Pavlovic","year":"2019","unstructured":"Pavlovic N, Rani B, Gerwins P, Heindryckx F. Platelets as key factors in hepatocellular carcinoma. Cancers. 2019;11:1022. https:\/\/doi.org\/10.3390\/cancers11071022.","journal-title":"Cancers"},{"key":"3362_CR16","doi-asserted-by":"publisher","first-page":"1277808","DOI":"10.3389\/fimmu.2023.1277808","volume":"14","author":"M Casari","year":"2023","unstructured":"Casari M, Siegl D, Deppermann C, Schuppan D. Macrophages and platelets in liver fibrosis and hepatocellular carcinoma. Front Immunol. 2023;14:1277808. https:\/\/doi.org\/10.3389\/fimmu.2023.1277808.","journal-title":"Front Immunol"},{"key":"3362_CR17","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1021\/acs.analchem.4c03855","volume":"97","author":"X Xie","year":"2025","unstructured":"Xie X, Xiang J, Zhao H, Tong B, Zhang L, Kang X, et al. Integrative quantitative analysis of platelet proteome and site-specific glycoproteome reveals diagnostic potential of platelet glycoproteins for liver cancer. Anal Chem. 2025;97:1546\u201356. https:\/\/doi.org\/10.1021\/acs.analchem.4c03855.","journal-title":"Anal Chem"},{"key":"3362_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41392-025-02198-8","volume":"10","author":"Y Tian","year":"2025","unstructured":"Tian Y, Zong Y, Pang Y, Zheng Z, Ma Y, Zhang C, et al. Platelets and diseases: signal transduction and advances in targeted therapy. Signal Transduct Target Ther. 2025;10:159. https:\/\/doi.org\/10.1038\/s41392-025-02198-8.","journal-title":"Signal Transduct Target Ther"},{"key":"3362_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12964-022-00887-3","volume":"20","author":"X Wang","year":"2022","unstructured":"Wang X, Zhao S, Wang Z, Gao T. Platelets involved tumor cell EMT during circulation: communications and interventions. Cell Commun Signal: CCS. 2022;20:82. https:\/\/doi.org\/10.1186\/s12964-022-00887-3.","journal-title":"Cell Commun Signal: CCS"},{"key":"3362_CR20","doi-asserted-by":"publisher","first-page":"217161","DOI":"10.1016\/j.canlet.2024.217161","volume":"600","author":"M Lu","year":"2024","unstructured":"Lu M, Gong X, Zhang Y-M, Guo Y-W, Zhu Y, Zeng X-B, et al. Platelets promote primary hepatocellular carcinoma metastasis through TGF-\u03b21-mediated cancer cell autophagy. Cancer Lett. 2024;600:217161. https:\/\/doi.org\/10.1016\/j.canlet.2024.217161.","journal-title":"Cancer Lett"},{"key":"3362_CR21","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.7150\/jca.103757","volume":"16","author":"C Zhong","year":"2025","unstructured":"Zhong C, Wang W, Yao Y, Lian S, Xie X, Xu J, et al. TGF-\u03b2 secreted by cancer cells-platelets interaction activates cancer metastasis potential by inducing metabolic reprogramming and bioenergetic adaptation. J Cancer. 2025;16:1310\u201323. https:\/\/doi.org\/10.7150\/jca.103757.","journal-title":"J Cancer"},{"key":"3362_CR22","doi-asserted-by":"publisher","first-page":"106180","DOI":"10.1016\/j.phrs.2022.106180","volume":"178","author":"L Cao","year":"2022","unstructured":"Cao L, Zhang Y, Mi J, Shi Z, Fang Z, Jia D, et al. \u03b1-hederin inhibits the platelet activating factor-induced metastasis of HCC cells through disruption of PAF\/PTAFR axis cascaded STAT3\/MMP-2 expression. Pharmacol Res. 2022;178:106180. https:\/\/doi.org\/10.1016\/j.phrs.2022.106180.","journal-title":"Pharmacol Res"},{"key":"3362_CR23","doi-asserted-by":"publisher","first-page":"216674","DOI":"10.1016\/j.canlet.2024.216674","volume":"585","author":"J-H Gao","year":"2024","unstructured":"Gao J-H, He A-D, Liu L-M, Zhou Y-J, Guo Y-W, Lu M, et al. Direct interaction of platelet with tumor cell aggravates hepatocellular carcinoma metastasis by activating TLR4\/ADAM10\/CX3CL1 axis. Cancer Lett. 2024;585:216674. https:\/\/doi.org\/10.1016\/j.canlet.2024.216674.","journal-title":"Cancer Lett"},{"key":"3362_CR24","doi-asserted-by":"publisher","first-page":"167734","DOI":"10.1016\/j.bbadis.2025.167734","volume":"1871","author":"G Luo","year":"2025","unstructured":"Luo G, Zhu S, He L, Liu Q, Xu C, Yao Q, et al. Platelets promote metastasis of intrahepatic cholangiocarcinoma through activation of TGF-\u03b2\/Smad2 pathway. Biochim Biophys Acta Mol Basis Dis. 2025;1871:167734. https:\/\/doi.org\/10.1016\/j.bbadis.2025.167734.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"3362_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41556-018-0195-z","volume":"21","author":"D Pei","year":"2019","unstructured":"Pei D, Shu X, Gassama-Diagne A, Thiery JP. Mesenchymal-epithelial transition in development and reprogramming. Nat Cell Biol. 2019;21:44\u201353. https:\/\/doi.org\/10.1038\/s41556-018-0195-z.","journal-title":"Nat Cell Biol"},{"key":"3362_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.semcancer.2025.02.001","volume":"110","author":"Z Chen","year":"2025","unstructured":"Chen Z, Xu L, Yuan Y, Zhang S, Xue R. Metabolic crosstalk between platelets and cancer: mechanisms, functions, and therapeutic potential. Semin Cancer Biol. 2025;110:65\u201382. https:\/\/doi.org\/10.1016\/j.semcancer.2025.02.001.","journal-title":"Semin Cancer Biol"},{"key":"3362_CR27","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ccell.2022.08.004","volume":"40","author":"C Ma","year":"2022","unstructured":"Ma C, Fu Q, Diggs LP, McVey JC, McCallen J, Wabitsch S, et al. Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. Cancer Cell. 2022;40:986\u2013e9985. https:\/\/doi.org\/10.1016\/j.ccell.2022.08.004.","journal-title":"Cancer Cell"},{"key":"3362_CR28","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41568-022-00520-y","volume":"22","author":"D Senft","year":"2022","unstructured":"Senft D. Platelets limit liver tumours. Nat Rev Cancer. 2022;22:608. https:\/\/doi.org\/10.1038\/s41568-022-00520-y.","journal-title":"Nat Rev Cancer"},{"key":"3362_CR29","doi-asserted-by":"publisher","first-page":"2304963","DOI":"10.1080\/2162402X.2024.2304963","volume":"13","author":"M Zhou","year":"2024","unstructured":"Zhou M, Feng Y, Zhang X, Chen J, Yao N, Fu S, et al. Platelet-derived microparticles adoptively transfer integrin \u03b23 to promote antitumor effect of tumor-infiltrating T cells. Oncoimmunology. 2024;13:2304963. https:\/\/doi.org\/10.1080\/2162402X.2024.2304963.","journal-title":"Oncoimmunology"},{"key":"3362_CR30","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1002\/mco2.350","volume":"4","author":"K Liao","year":"2023","unstructured":"Liao K, Zhang X, Liu J, Teng F, He Y, Cheng J, et al. The role of platelets in the regulation of tumor growth and metastasis: the mechanisms and targeted therapy. Medcomm. 2023;4:e350. https:\/\/doi.org\/10.1002\/mco2.350.","journal-title":"Medcomm"},{"key":"3362_CR31","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/liv.15183","volume":"42","author":"A Zanetto","year":"2022","unstructured":"Zanetto A, Campello E, Pelizzaro F, Farinati F, Burra P, Simioni P, et al. Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. Liver Int: Off J Int Assoc Study Liver. 2022;42:1229\u201340. https:\/\/doi.org\/10.1111\/liv.15183.","journal-title":"Liver Int: Off J Int Assoc Study Liver"},{"key":"3362_CR32","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1182\/blood-2017-05-743187","volume":"131","author":"XR Xu","year":"2018","unstructured":"Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood. 2018;131:1777\u201389. https:\/\/doi.org\/10.1182\/blood-2017-05-743187.","journal-title":"Blood"},{"key":"3362_CR33","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3389\/fimmu.2014.00649","volume":"5","author":"A Assinger","year":"2014","unstructured":"Assinger A. Platelets and infection - an emerging role of platelets in viral infection. Front Immunol. 2014;5:649. https:\/\/doi.org\/10.3389\/fimmu.2014.00649.","journal-title":"Front Immunol"},{"key":"3362_CR34","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.cell.2015.03.005","volume":"161","author":"LG Guidotti","year":"2015","unstructured":"Guidotti LG, Inverso D, Sironi L, Di Lucia P, Fioravanti J, Ganzer L, et al. Immunosurveillance of the liver by intravascular effector CD8(+) T cells. Cell. 2015;161:486\u2013500. https:\/\/doi.org\/10.1016\/j.cell.2015.03.005.","journal-title":"Cell"},{"key":"3362_CR35","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.3390\/cancers17142391","volume":"17","author":"N Kluz","year":"2025","unstructured":"Kluz N, Grabowska H, Chmiel P, Rynkiewicz K, Skrobucha A, Wysoki\u0144ska E, et al. Platelets in hepatocellular carcinoma-from pathogenesis to targeted therapy. Cancers. 2025;17:2391. https:\/\/doi.org\/10.3390\/cancers17142391.","journal-title":"Cancers"},{"key":"3362_CR36","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.3748\/wjg.v28.i30.4061","volume":"28","author":"P Gallo","year":"2022","unstructured":"Gallo P, Terracciani F, Di Pasquale G, Esposito M, Picardi A, Vespasiani-Gentilucci U. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures. World J Gastroenterol. 2022;28:4061\u201374. https:\/\/doi.org\/10.3748\/wjg.v28.i30.4061.","journal-title":"World J Gastroenterol"},{"key":"3362_CR37","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1111\/liv.14560","volume":"40","author":"P-H Liu","year":"2020","unstructured":"Liu P-H, Hsu C-Y, Su C-W, Huang Y-H, Hou M-C, Rich NE, et al. Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver Int: Off J Int Assoc Study Liver. 2020;40:2522\u201334. https:\/\/doi.org\/10.1111\/liv.14560.","journal-title":"Liver Int: Off J Int Assoc Study Liver"},{"key":"3362_CR38","doi-asserted-by":"publisher","unstructured":"Dz L, Qk JG, Xj S, Xl H. Prognostic prediction of the platelet-to-lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis. Transl Cancer Res. 2022;11. https:\/\/doi.org\/10.21037\/tcr-22-1197.","DOI":"10.21037\/tcr-22-1197"},{"key":"3362_CR39","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3390\/cells10081917","volume":"10","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee S, Kar A, Khatun N, Datta P, Biswas A, Barik S. Familiarity breeds strategy: In silico untangling of the molecular complexity on course of autoimmune liver disease-to-hepatocellular carcinoma transition predicts novel transcriptional signatures. Cells. 2021;10:1917. https:\/\/doi.org\/10.3390\/cells10081917.","journal-title":"Cells"},{"key":"3362_CR40","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2147\/JHC.S511263","volume":"12","author":"S Munker","year":"2025","unstructured":"Munker S, Rodriguez I, Bernhart K, Ben Khaled N, Findik M, Siegmund LK, et al. Prognostic significance of elevated platelet count (>\u2009200 x 10^9 per L) in BCLC stages B and C of hepatocellular carcinoma: a retrospective multicenter analysis. J Hepatocell Carcinoma. 2025;12:855\u201364. https:\/\/doi.org\/10.2147\/JHC.S511263.","journal-title":"J Hepatocell Carcinoma"},{"key":"3362_CR41","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/curroncol29030124","volume":"29","author":"C Schrecker","year":"2022","unstructured":"Schrecker C, Waidmann O, El Youzouri H, Trojan J, Schnitzbauer AA, Bechstein WO, et al. Low platelet count predicts reduced survival in potentially resectable hepatocellular carcinoma. Curr Oncol (Tor Ont). 2022;29:1475\u201387. https:\/\/doi.org\/10.3390\/curroncol29030124.","journal-title":"Curr Oncol (Tor Ont)"},{"key":"3362_CR42","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3390\/cancers16071293","volume":"16","author":"L Kraj","year":"2024","unstructured":"Kraj L, Chmiel P, Gryziak M, Grabowska-Derlatka L, Szyma\u0144ski \u0141, Wysoki\u0144ska E. Impact of thrombocytopenia on survival in patients with hepatocellular carcinoma: updated meta-analysis and systematic review. Cancers. 2024;16:1293. https:\/\/doi.org\/10.3390\/cancers16071293.","journal-title":"Cancers"},{"key":"3362_CR43","doi-asserted-by":"publisher","first-page":"351","DOI":"10.5582\/bst.2025.01067","volume":"19","author":"X Wang","year":"2025","unstructured":"Wang X, Wang P, Tang B, Xu J, Wang B, Gu L, et al. Platelet count as a double-edged sword: the impact of thrombocytosis and thrombocytopenia on long-term outcomes after hepatic resection for hepatocellular carcinoma. Biosci Trends. 2025;19:351\u201360. https:\/\/doi.org\/10.5582\/bst.2025.01067.","journal-title":"Biosci Trends"},{"key":"3362_CR44","doi-asserted-by":"publisher","first-page":"11460","DOI":"10.3390\/ijms231911460","volume":"23","author":"S-H Chen","year":"2022","unstructured":"Chen S-H, Tsai S-C, Lu H-C. Platelets as a Gauge of Liver Disease Kinetics? Int J Mol Sci. 2022;23:11460. https:\/\/doi.org\/10.3390\/ijms231911460.","journal-title":"Int J Mol Sci"},{"key":"3362_CR45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000489833","volume":"8","author":"B Scheiner","year":"2019","unstructured":"Scheiner B, Kirstein M, Popp S, Hucke F, Bota S, Rohr-Udilova N, et al. Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma. Liver Cancer. 2019;8:203\u201317. https:\/\/doi.org\/10.1159\/000489833.","journal-title":"Liver Cancer"},{"key":"3362_CR46","doi-asserted-by":"publisher","first-page":"104380","DOI":"10.1016\/j.critrevonc.2024.104380","volume":"199","author":"N Tuerhong","year":"2024","unstructured":"Tuerhong N, Yang Y, Wang C, Huang P, Li Q. Interactions between platelets and the cancer immune microenvironment. Crit Rev Oncol Hematol. 2024;199:104380. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104380.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3362_CR47","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-018-0669-2","volume":"11","author":"M Schlesinger","year":"2018","unstructured":"Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11:125. https:\/\/doi.org\/10.1186\/s13045-018-0669-2.","journal-title":"J Hematol Oncol"},{"key":"3362_CR48","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-019-0739-0","volume":"12","author":"Q Wu","year":"2019","unstructured":"Wu Q, Zhou L, Lv D, Zhu X, Tang H. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression. J Hematol Oncol. 2019;12:53. https:\/\/doi.org\/10.1186\/s13045-019-0739-0.","journal-title":"J Hematol Oncol"},{"key":"3362_CR49","doi-asserted-by":"publisher","first-page":"1200201","DOI":"10.3389\/fimmu.2023.1200201","volume":"14","author":"T Li","year":"2023","unstructured":"Li T, Jiao J, Ke H, Ouyang W, Wang L, Pan J, et al. Role of exosomes in the development of the immune microenvironment in hepatocellular carcinoma. Front Immunol. 2023;14:1200201. https:\/\/doi.org\/10.3389\/fimmu.2023.1200201.","journal-title":"Front Immunol"},{"key":"3362_CR50","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.3389\/fimmu.2019.01805","volume":"10","author":"AL Palacios-Acedo","year":"2019","unstructured":"Palacios-Acedo AL, M\u00e8ge D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Platelets, thrombo-inflammation, and cancer: collaborating with the enemy. Front Immunol. 2019;10:1805. https:\/\/doi.org\/10.3389\/fimmu.2019.01805.","journal-title":"Front Immunol"},{"key":"3362_CR51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41568-023-00639-6","volume":"24","author":"S Li","year":"2024","unstructured":"Li S, Lu Z, Wu S, Chu T, Li B, Qi F, et al. The dynamic role of platelets in cancer progression and their therapeutic implications. Nat Rev Cancer. 2024;24:72\u201387. https:\/\/doi.org\/10.1038\/s41568-023-00639-6.","journal-title":"Nat Rev Cancer"},{"key":"3362_CR52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-023-01759-1","volume":"22","author":"Z Hu","year":"2023","unstructured":"Hu Z, Chen G, Zhao Y, Gao H, Li L, Yin Y, et al. Exosome-derived circCCAR1 promotes CD8\u2009+\u2009T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma. Mol Cancer. 2023;22:55. https:\/\/doi.org\/10.1186\/s12943-023-01759-1.","journal-title":"Mol Cancer"},{"key":"3362_CR53","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41467-024-55577-0","volume":"16","author":"T Lan","year":"2025","unstructured":"Lan T, Gao F, Cai Y, Lv Y, Zhu J, Liu H, et al. The protein circPETH-147aa regulates metabolic reprogramming in hepatocellular carcinoma cells to remodel immunosuppressive microenvironment. Nat Commun. 2025;16:333. https:\/\/doi.org\/10.1038\/s41467-024-55577-0.","journal-title":"Nat Commun"},{"key":"3362_CR54","doi-asserted-by":"publisher","first-page":"107419","DOI":"10.1016\/j.phrs.2024.107419","volume":"209","author":"L Cheng","year":"2024","unstructured":"Cheng L, Zhang L, Wang X, Wang Y, Yu J, Li M, et al. Extracellular vesicles in the HCC microenvironment: implications for therapy and biomarkers. Pharmacol Res. 2024;209:107419. https:\/\/doi.org\/10.1016\/j.phrs.2024.107419.","journal-title":"Pharmacol Res"},{"key":"3362_CR55","doi-asserted-by":"publisher","first-page":"1227150","DOI":"10.3389\/fimmu.2023.1227150","volume":"14","author":"H-Z Xu","year":"2023","unstructured":"Xu H-Z, Lin X-Y, Xu Y-X, Xue H-B, Lin S, Xu T-W. An emerging research: the role of hepatocellular carcinoma-derived exosomal circRNAs in the immune microenvironment. Front Immunol. 2023;14:1227150. https:\/\/doi.org\/10.3389\/fimmu.2023.1227150.","journal-title":"Front Immunol"},{"key":"3362_CR56","doi-asserted-by":"publisher","first-page":"116409","DOI":"10.1016\/j.biopha.2024.116409","volume":"173","author":"Q Huang","year":"2024","unstructured":"Huang Q, Zhong X, Li J, Hu R, Yi J, Sun J, et al. Exosomal ncRNAs: multifunctional contributors to the immunosuppressive tumor microenvironment of hepatocellular carcinoma. Biomed Pharmacother = Biomed Pharmacother. 2024;173:116409. https:\/\/doi.org\/10.1016\/j.biopha.2024.116409.","journal-title":"Biomed Pharmacother = Biomed Pharmacother"},{"key":"3362_CR57","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.2147\/IJN.S404925","volume":"18","author":"X Lu","year":"2023","unstructured":"Lu X, Guo H, Wei X, Lu D, Shu W, Song Y, et al. Current status and prospect of delivery vehicle based on mesenchymal stem cell-derived exosomes in liver diseases. Int J Nanomed. 2023;18:2873\u201390. https:\/\/doi.org\/10.2147\/IJN.S404925.","journal-title":"Int J Nanomed"},{"key":"3362_CR58","doi-asserted-by":"publisher","first-page":"4744","DOI":"10.7150\/ijbs.86767","volume":"19","author":"W Jia","year":"2023","unstructured":"Jia W, Liang S, Lin W, Li S, Yuan J, Jin M, et al. Hypoxia-induced exosomes facilitate lung pre-metastatic niche formation in hepatocellular carcinoma through the miR-4508-RFX1-IL17A-p38 MAPK-NF-\u03baB pathway. Int J Biol Sci. 2023;19:4744\u201362. https:\/\/doi.org\/10.7150\/ijbs.86767.","journal-title":"Int J Biol Sci"},{"key":"3362_CR59","doi-asserted-by":"publisher","first-page":"112282","DOI":"10.1016\/j.intimp.2024.112282","volume":"138","author":"H Shang","year":"2024","unstructured":"Shang H, Lu L, Fan M, Lu Y, Shi X, Lu H. Exosomal circHIF1A derived from hypoxic-induced carcinoma-associated fibroblasts promotes hepatocellular carcinoma cell malignant phenotypes and immune escape. Int Immunopharmacol. 2024;138:112282. https:\/\/doi.org\/10.1016\/j.intimp.2024.112282.","journal-title":"Int Immunopharmacol"},{"key":"3362_CR60","doi-asserted-by":"publisher","first-page":"156750","DOI":"10.1016\/j.phymed.2025.156750","volume":"141","author":"X Tu","year":"2025","unstructured":"Tu X, Lin W, Zhai X, Liang S, Huang G, Wang J, et al. Oleanolic acid inhibits M2 macrophage polarization and potentiates anti-PD-1 therapy in hepatocellular carcinoma by targeting miR-130b-3p-PTEN-PI3K-akt signaling and glycolysis. Phytomed. Int J Phytother Phytopharm. 2025;141:156750. https:\/\/doi.org\/10.1016\/j.phymed.2025.156750.","journal-title":"Int J Phytother Phytopharm"},{"key":"3362_CR61","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-024-02082-z","volume":"23","author":"W Zhang","year":"2024","unstructured":"Zhang W, Xu C, Yang Z, Zhou J, Peng W, Zhang X, et al. Circular RNAs in tumor immunity and immunotherapy. Mol Cancer. 2024;23:171. https:\/\/doi.org\/10.1186\/s12943-024-02082-z.","journal-title":"Mol Cancer"},{"key":"3362_CR62","doi-asserted-by":"publisher","first-page":"1523190","DOI":"10.3389\/fimmu.2025.1523190","volume":"16","author":"S Zhao","year":"2025","unstructured":"Zhao S, Chen F, Hu L, Li X, Gao Z, Chen M, et al. Long non-coding rnas as key modulators of the immune microenvironment in hepatocellular carcinoma: implications for immunotherapy. Front Immunol. 2025;16:1523190. https:\/\/doi.org\/10.3389\/fimmu.2025.1523190.","journal-title":"Front Immunol"},{"key":"3362_CR63","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s41467-025-56878-8","volume":"16","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Yu H, Li J, Qian J, Li M, Zhang X, et al. A glucose-enriched lung pre-metastatic niche triggered by matrix stiffness-tuned exosomal miRNAs in hepatocellular carcinoma. Nat Commun. 2025;16:1736. https:\/\/doi.org\/10.1038\/s41467-025-56878-8.","journal-title":"Nat Commun"},{"key":"3362_CR64","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41419-024-07004-x","volume":"15","author":"Y Yang","year":"2024","unstructured":"Yang Y, Chen X-Q, Jia Y-X, Ma J, Xu D, Xiang Z-L. Circ-0044539 promotes lymph node metastasis of hepatocellular carcinoma through exosomal-miR-29a-3p. Cell Death Dis. 2024;15:630. https:\/\/doi.org\/10.1038\/s41419-024-07004-x.","journal-title":"Cell Death Dis"},{"key":"3362_CR65","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12943-024-02101-z","volume":"23","author":"Y-T Chan","year":"2024","unstructured":"Chan Y-T, Zhang C, Wu J, Lu P, Xu L, Yuan H, et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer. 2024;23:189. https:\/\/doi.org\/10.1186\/s12943-024-02101-z.","journal-title":"Mol Cancer"},{"key":"3362_CR66","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s13046-022-02482-3","volume":"41","author":"Y Li","year":"2022","unstructured":"Li Y, Wu A, Chen L, Cai A, Hu Y, Zhou Z, et al. Hsa_circ_0000098 is a novel therapeutic target that promotes hepatocellular carcinoma development and resistance to doxorubicin. J Exp Clin Cancer Res: CR. 2022;41:267. https:\/\/doi.org\/10.1186\/s13046-022-02482-3.","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"3362_CR67","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/CBM-182076","volume":"24","author":"X Zuo","year":"2019","unstructured":"Zuo X, Kong W, Feng L, Zhang H, Meng X, Chen W. Elevated platelet distribution width predicts poor prognosis in hepatocellular carcinoma. Cancer Biomark: Dis Markers. 2019;24:307\u201313. https:\/\/doi.org\/10.3233\/CBM-182076.","journal-title":"Cancer Biomark: Dis Markers"},{"key":"3362_CR68","doi-asserted-by":"publisher","first-page":"100995","DOI":"10.1016\/j.jhepr.2023.100995","volume":"6","author":"O \u00d6cal","year":"2024","unstructured":"\u00d6cal O, Kimm MA, Hoang TPT, Pech M, \u00d6cal E, Ben Khaled N, et al. Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization. JHEP Rep: Innov Hepatol. 2024;6:100995. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100995.","journal-title":"JHEP Rep: Innov Hepatol"},{"key":"3362_CR69","doi-asserted-by":"publisher","first-page":"111510","DOI":"10.1016\/j.intimp.2024.111510","volume":"130","author":"H Liu","year":"2024","unstructured":"Liu H, Gan X-M, Sun J-M, Yang Q, Zhang D-Z, Zuo Y-Q, et al. Transcatheter arterial chemoembolisation combined with lenvatinib and cabozantinib in the treatment of advanced hepatocellular carcinoma. Int Immunopharmacol. 2024;130:111510. https:\/\/doi.org\/10.1016\/j.intimp.2024.111510.","journal-title":"Int Immunopharmacol"},{"key":"3362_CR70","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40364-024-00722-6","volume":"13","author":"T He","year":"2025","unstructured":"He T, Xu B, Wang L-N, Wang Z-Y, Shi H-C, Zhong C-J, et al. The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy. Biomark Res. 2025;13:10. https:\/\/doi.org\/10.1186\/s40364-024-00722-6.","journal-title":"Biomark Res"},{"key":"3362_CR71","doi-asserted-by":"publisher","first-page":"175883592412970","DOI":"10.1177\/17588359241297080","volume":"16","author":"M Zuo","year":"2024","unstructured":"Zuo M, Wei R, Li D, Li W, An C. The AFCRPLITY score for predicting the prognosis of immunotherapy combined with local-regional therapy in unresectable hepatocellular carcinoma. Ther Adv Med Oncol. 2024;16:17588359241297080. https:\/\/doi.org\/10.1177\/17588359241297080.","journal-title":"Ther Adv Med Oncol"},{"key":"3362_CR72","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1007\/s00259-023-06260-x","volume":"50","author":"H Cai","year":"2023","unstructured":"Cai H, Li Z, Shi Q, Yang H, Xiao L, Li M, et al. Preclinical evaluation of 68Ga-radiolabeled trimeric affibody for PDGFR\u03b2-targeting PET imaging of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2023;50:2952\u201361. https:\/\/doi.org\/10.1007\/s00259-023-06260-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3362_CR73","doi-asserted-by":"publisher","first-page":"e169598","DOI":"10.1172\/JCI169598","volume":"133","author":"EA Goethe","year":"2023","unstructured":"Goethe EA, Heimberger AB, Rao G. Aspirin and immunotherapy: a faustian bargain? J Clin Invest. 2023;133:e169598. https:\/\/doi.org\/10.1172\/JCI169598.","journal-title":"J Clin Invest"},{"key":"3362_CR74","doi-asserted-by":"publisher","first-page":"116018","DOI":"10.1016\/j.biopha.2023.116018","volume":"170","author":"Z-S Xie","year":"2024","unstructured":"Xie Z-S, Han X-Y, Zhou Z-Y, Li S-Y, Zhu J-Y, Zhang L, et al. Design and synthesis of dabigatran etexilate derivatives with inhibiting thrombin activity for hepatocellular carcinoma treatment. Biomed Pharmacother = Biomed Pharmacother. 2024;170:116018. https:\/\/doi.org\/10.1016\/j.biopha.2023.116018.","journal-title":"Biomed Pharmacother = Biomed Pharmacother"},{"key":"3362_CR75","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jhep.2013.05.040","volume":"59","author":"G Sitia","year":"2013","unstructured":"Sitia G, Iannacone M, Guidotti LG. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol. 2013;59:1135\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2013.05.040.","journal-title":"J Hepatol"},{"key":"3362_CR76","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jhep.2007.01.007","volume":"46","author":"M Iannacone","year":"2007","unstructured":"Iannacone M, Sitia G, Ruggeri ZM, Guidotti LG. HBV pathogenesis in animal models: recent advances on the role of platelets. J Hepatol. 2007;46:719\u201326. https:\/\/doi.org\/10.1016\/j.jhep.2007.01.007.","journal-title":"J Hepatol"},{"key":"3362_CR77","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/apt.16515","volume":"54","author":"RZH Tan","year":"2021","unstructured":"Tan RZH, Lockart I, Abdel Shaheed C, Danta M. Systematic review with meta-analysis: the effects of non-steroidal anti-inflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma. Aliment Pharmacol Ther. 2021;54:356\u201367. https:\/\/doi.org\/10.1111\/apt.16515.","journal-title":"Aliment Pharmacol Ther"},{"key":"3362_CR78","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/hep.32380","volume":"76","author":"H Jang","year":"2022","unstructured":"Jang H, Lee YB, Moon H, Chung J-W, Nam JY, Cho EJ, et al. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatol (Baltim Md). 2022;76:492\u2013501. https:\/\/doi.org\/10.1002\/hep.32380.","journal-title":"Hepatol (Baltim Md)"},{"key":"3362_CR79","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa1912035","volume":"382","author":"TG Simon","year":"2020","unstructured":"Simon TG, Duberg A-S, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N Engl J Med. 2020;382:1018\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1912035.","journal-title":"N Engl J Med"},{"key":"3362_CR80","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1186\/s12916-024-03802-4","volume":"22","author":"M Anson","year":"2024","unstructured":"Anson M, Poon JS, Henney AE, Riley D, Ibarbaru GH, Sieberhagen C, et al. The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study. BMC Med. 2024;22:574. https:\/\/doi.org\/10.1186\/s12916-024-03802-4.","journal-title":"BMC Med"},{"key":"3362_CR81","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3350\/cmh.2025.0528","volume":"32","author":"J Ahn","year":"2026","unstructured":"Ahn J, Hur MH, Shin H, Park MK, Won S, Park J, et al. Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis. Clin Mol Hepatol. 2026;32:339\u201352. https:\/\/doi.org\/10.3350\/cmh.2025.0528.","journal-title":"Clin Mol Hepatol"},{"key":"3362_CR82","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1111\/liv.15918","volume":"44","author":"M Moriguchi","year":"2024","unstructured":"Moriguchi M, Okuda K, Horiguchi G, Kataoka S, Seko Y, Yamaguchi K, et al. Safety\/efficacy of atezolizumab\u2009+\u2009bevacizumab during anti-platelet\/anticoagulation therapy in unresectable hepatocellular carcinoma. Liver Int: Off J Int Assoc Study Liver. 2024;44:1751\u201361. https:\/\/doi.org\/10.1111\/liv.15918.","journal-title":"Liver Int: Off J Int Assoc Study Liver"},{"key":"3362_CR83","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1111\/apt.18526","volume":"61","author":"K Park","year":"2025","unstructured":"Park K, Lee HW, Kim E, Choi W-M, Lee D, Shim JH, et al. Risk of variceal bleeding in patients receiving atezolizumab-bevacizumab treatment for hepatocellular carcinoma. Aliment Pharmacol Ther. 2025;61:1311\u20137. https:\/\/doi.org\/10.1111\/apt.18526.","journal-title":"Aliment Pharmacol Ther"},{"key":"3362_CR84","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jhep.2023.11.030","volume":"80","author":"BM Lehrich","year":"2024","unstructured":"Lehrich BM, Zhang J, Monga SP, Dhanasekaran R. Battle of the biopsies: role of tissue and liquid biopsy in hepatocellular carcinoma. J Hepatol. 2024;80:515\u201330. https:\/\/doi.org\/10.1016\/j.jhep.2023.11.030.","journal-title":"J Hepatol"},{"key":"3362_CR85","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12951-019-0494-y","volume":"17","author":"H Wang","year":"2019","unstructured":"Wang H, Wu J, Williams GR, Fan Q, Niu S, Wu J, et al. Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery. J Nanobiotechnol. 2019;17:60. https:\/\/doi.org\/10.1186\/s12951-019-0494-y.","journal-title":"J Nanobiotechnol"},{"key":"3362_CR86","doi-asserted-by":"publisher","first-page":"113973","DOI":"10.1016\/j.colsurfb.2024.113973","volume":"240","author":"Y Wu","year":"2024","unstructured":"Wu Y, Fan Q, Zhou J, Hu H, Liao Z, Tang X, et al. Biomimetic platelet-like nanoparticles enhance targeted hepatocellular carcinoma therapy. Colloids Surf B Biointerfaces. 2024;240:113973. https:\/\/doi.org\/10.1016\/j.colsurfb.2024.113973.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3362_CR87","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12951-021-01095-w","volume":"19","author":"Z Li","year":"2021","unstructured":"Li Z, Yang G, Han L, Wang R, Gong C, Yuan Y. Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma. J Nanobiotechnol. 2021;19:360. https:\/\/doi.org\/10.1186\/s12951-021-01095-w.","journal-title":"J Nanobiotechnol"},{"key":"3362_CR88","doi-asserted-by":"publisher","first-page":"23829","DOI":"10.1021\/acsnano.3c07885","volume":"17","author":"H Guo","year":"2023","unstructured":"Guo H, Liu Y, Li X, Wang H, Mao D, Wei L, et al. Magnetic metal-organic framework-based nanoplatform with platelet membrane coating as a synergistic programmed cell death protein 1 inhibitor against hepatocellular carcinoma. ACS Nano. 2023;17:23829\u201349. https:\/\/doi.org\/10.1021\/acsnano.3c07885.","journal-title":"ACS Nano"},{"key":"3362_CR89","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1039\/d0tb00735h","volume":"8","author":"L Wu","year":"2020","unstructured":"Wu L, Xie W, Zan H-M, Liu Z, Wang G, Wang Y, et al. Platelet membrane-coated nanoparticles for targeted drug delivery and local chemo-photothermal therapy of orthotopic hepatocellular carcinoma. J Mater Chem B. 2020;8:4648\u201359. https:\/\/doi.org\/10.1039\/d0tb00735h.","journal-title":"J Mater Chem B"},{"key":"3362_CR90","doi-asserted-by":"publisher","first-page":"6293","DOI":"10.2147\/IJN.S436373","volume":"18","author":"L Yang","year":"2023","unstructured":"Yang L, Zhang K, Zheng D, Bai Y, Yue D, Wu L, et al. Platelet-based nanoparticles with stimuli-responsive for anti-tumor therapy. Int J Nanomed. 2023;18:6293\u2013309. https:\/\/doi.org\/10.2147\/IJN.S436373.","journal-title":"Int J Nanomed"},{"key":"3362_CR91","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/ijc.33915","volume":"150","author":"H Tanaka","year":"2022","unstructured":"Tanaka H, Horioka K, Hasebe T, Sawada K, Nakajima S, Konishi H, et al. Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: a novel therapy exploiting tumor-platelet interactions. Int J Cancer. 2022;150:1640\u201353. https:\/\/doi.org\/10.1002\/ijc.33915.","journal-title":"Int J Cancer"},{"key":"3362_CR92","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jconrel.2024.08.044","volume":"374","author":"C Chen","year":"2024","unstructured":"Chen C, Pan Y, Yang X, Li H, Cai X, He S, et al. Liver-targeting chimeras as a potential modality for the treatment of liver diseases. J Control Release: Off J Control Release Soc. 2024;374:627\u201338. https:\/\/doi.org\/10.1016\/j.jconrel.2024.08.044.","journal-title":"J Control Release: Off J Control Release Soc"},{"key":"3362_CR93","doi-asserted-by":"publisher","first-page":"120395","DOI":"10.1016\/j.ijpharm.2021.120395","volume":"598","author":"SS Kunde","year":"2021","unstructured":"Kunde SS, Wairkar S. Platelet membrane camouflaged nanoparticles: biomimetic architecture for targeted therapy. Int J Pharm. 2021;598:120395. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120395.","journal-title":"Int J Pharm"},{"key":"3362_CR94","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","volume":"6","author":"S Qin","year":"2021","unstructured":"Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6:559\u201368. https:\/\/doi.org\/10.1016\/S2468-1253(21)00109-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3362_CR95","doi-asserted-by":"publisher","first-page":"101287","DOI":"10.1016\/j.jhepr.2024.101287","volume":"7","author":"Y Zhai","year":"2025","unstructured":"Zhai Y, Wang L, Zhao H, Wu F, Xin L, Ye F, et al. Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and\/or hepatic vein tumor thrombosis. JHEP Rep: Innov Hepatol. 2025;7:101287. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101287.","journal-title":"JHEP Rep: Innov Hepatol"},{"key":"3362_CR96","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s13402-024-01015-8","volume":"47","author":"R Sun","year":"2024","unstructured":"Sun R, Gou Y, Pan L, He Q, Zhou Y, Luo Y, et al. Hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for unresectable hepatocellular carcinoma: a retrospective single-arm study. Cell Oncol. 2024;47:2265\u201376. https:\/\/doi.org\/10.1007\/s13402-024-01015-8.","journal-title":"Cell Oncol"},{"key":"3362_CR97","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.3390\/cancers11101568","volume":"11","author":"Q Lai","year":"2019","unstructured":"Lai Q, Vitale A, Manzia TM, Foschi FG, Levi Sandri GB, Gambato M, et al. Platelets and hepatocellular cancer: bridging the bench to the clinics. Cancers. 2019;11:1568. https:\/\/doi.org\/10.3390\/cancers11101568.","journal-title":"Cancers"},{"key":"3362_CR98","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000534127","volume":"13","author":"M Iavarone","year":"2024","unstructured":"Iavarone M, Alimenti E, Tada T, Shimose S, Suda G, Yoo C, et al. Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib. Liver Cancer. 2024;13:215\u201326. https:\/\/doi.org\/10.1159\/000534127.","journal-title":"Liver Cancer"},{"key":"3362_CR99","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12885-024-12006-1","volume":"24","author":"X Da","year":"2024","unstructured":"Da X, Cao B, Mo J, Xiang Y, Hu H, Qiu C, et al. Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets. BMC Cancer. 2024;24:273. https:\/\/doi.org\/10.1186\/s12885-024-12006-1.","journal-title":"BMC Cancer"},{"key":"3362_CR100","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12967-024-05230-7","volume":"22","author":"AM El-Derby","year":"2024","unstructured":"El-Derby AM, Khedr MA, Ghoneim NI, Gabr MM, Khater SM, El-Badri N. Plasma-derived extracellular matrix for xenofree and cost-effective organoid modeling for hepatocellular carcinoma. J Transl Med. 2024;22:487. https:\/\/doi.org\/10.1186\/s12967-024-05230-7.","journal-title":"J Transl Med"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03362-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03362-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03362-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:20:58Z","timestamp":1788924058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03362-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":100,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["3362"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03362-y","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"7 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"247"}}